Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSEN1 | P49768 | 18/20 | 0.57 |
| ▸ | PSEN2 | P49810 | 18/20 | 0.57 |
| ▸ | APH1B | Q8WW43 | 18/20 | 0.57 |
| ▸ | NCSTN | Q92542 | 18/20 | 0.57 |
| ▸ | APH1A | Q96BI3 | 18/20 | 0.57 |
| ▸ | PSENEN | Q9NZ42 | 18/20 | 0.57 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.57 |
| ▸ | APP | P05067 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | ALDH1A3 | P47895 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29940580 | 1.00 | PSEN1 (0.57) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL8149129 | 0.87 | PSEN1 (0.59) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL1238787 | 0.86 | ALDH1A1 (0.50) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL1238894 | 0.85 | PSEN1 (0.44) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL6979060 | 0.85 | PSEN1 (0.62) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL1238784 | 0.85 | ALDH1A1 (0.51) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL12157438 | 0.84 | PSEN1 (0.55) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL7834653 | 0.84 | PSEN1 (0.61) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL28908415 | 0.84 | PSEN1 (0.56) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL29940697 | 0.84 | PSEN1 (0.56) | PSEN1PSEN2APH1BNCSTNAPH1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 210 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110194743-B | Phenyl (3-methoxy-4- (4-methyl-1H-imidazole-1-yl) phenyl) ketone compound | 云南大学 | 2022-11-11 | — | — | CN | claimed |
| EP-2261218-B1 | Imidazole compound for use as an intermediate in the production of cinnamide compounds | EISAI R&D MAN CO LTD (JP) | 2013-04-03 | — | — | EP | claimed |
| EP-2261218-A2 | Process for preparing phenyl-, pyridinyl- or pyrimidinyl-substituted imidazoles | Eisai R&D Management Co., Ltd. (JP) | 2010-12-15 | — | — | EP | claimed |
| US-7687640-B2 | Cinnamide compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-03-30 | — | — | US | claimed |
| EP-2147917-A1 | ONE-POT PRODUCTION PROCESS FOR CINNAMIDE DERIVATIVE | Eisai R&D Management Co., Ltd. (JP) | 2010-01-27 | — | — | EP | claimed |
| US-20090281310-A1 | 3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzaldehyde; inhibits production of A beta 40 and A beta 42 from amyloid precursor protein ; Alzheimer's disease and Down syndrome | EISAI R&D MANAGEMENT CO., LTD. | 2009-11-12 | — | — | US | claimed |
| US-20090270623-A1 | PROCESS FOR PRODUCTION OF CINNAMIDE DERIVATIVE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-10-29 | — | — | US | claimed |
| US-20080306272-A1 | ONE-POT METHODS FOR PREPARING CINNAMIDE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2008-12-11 | — | — | US | claimed |
| EP-1950211-A1 | PROCESS FOR PRODUCTION OF CINNAMAMIDE DERIVATIVE | Eisai R&D Management Co., Ltd. (JP) | 2008-07-30 | — | — | EP | claimed |
| CN-110194746-B | Compound for treating alzheimer disease, preparation method and application thereof | 云南大学 | 2022-11-18 | — | — | CN | disclosed |
| CN-110194743-B | Phenyl (3-methoxy-4- (4-methyl-1H-imidazole-1-yl) phenyl) ketone compound | 云南大学 | 2022-11-11 | — | — | CN | disclosed |
| CN-110194743-B | Phenyl (3-methoxy-4- (4-methyl-1H-imidazole-1-yl) phenyl) ketone compound | 云南大学 | 2022-11-11 | — | — | CN | disclosed |
| CN-110194744-B | Compound for inhibiting beta-amyloid protein generation and preparation method and application thereof | 云南大学 | 2022-11-11 | — | — | CN | disclosed |
| CN-110194744-A | A kind of compound and its preparation method and application for inhibiting beta-amyloid protein to generate | 云南大学 | 2019-09-03 | — | — | CN | disclosed |
| EP-1757591-A1 | CINNAMIDE COMPOUND | Eisai R&D Management Co., Ltd. (JP) | 2007-02-28 | — | — | EP | disclosed |
| US-20060241038-A1 | Therapeutic agent for Abeta related disorders | EISAI CO., LTD. (JP) | 2006-10-26 | — | — | US | disclosed |
| WO-2006112551-A2 | A THERAPEUTIC AGENT FOR Aβ RELATED DISORDERS | EISAI CO., LTD. (JP) | 2006-10-26 | — | — | WO | disclosed |
| WO-2006112550-A2 | A THERAPEUTIC AGENT FOR Aβ RELATED DISORDERS | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2006-10-26 | — | — | WO | disclosed |
| WO-2006112552-A2 | THERAPEUTIC AGENTS FOR ABETA RELATED DISORDERS | EISAI CO., LTD. (JP) | 2006-10-26 | — | — | WO | disclosed |
| US-20060004013-A1 | Alzheimer's disease, senile dementia, Down syndrome or amyloidosis; 3E)-1-[(1S)-1-(4-fluorophenyl)ethyl]-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]piperidin-2-one; imidazolyl-functional compounds inhibit production of Amyloid beta 40 and Amyloid beta 42; low hygroscopicity; good solubility | EISAI CO., LTD. | 2006-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281310-A1 | 3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzaldehyde; inhibits production of A beta 40 and A beta 42 from amyloid precursor protein ; Alzheimer's disease and Down syndrome | APP, PSEN1, BACE1 | PSEN1 2/4885PSEN2 4/4885APH1B 18/4885 |
| US-20090270623-A1 | PROCESS FOR PRODUCTION OF CINNAMIDE DERIVATIVE | CBR1, H1-0, CBR3 | PSEN1 4651/4885PSEN2 4686/4885APH1B 3878/4885 |
| US-20080306272-A1 | ONE-POT METHODS FOR PREPARING CINNAMIDE DERIVATIVES | TAS2R41, TAS2R1, CUL1 | PSEN1 4343/4885PSEN2 4645/4885APH1B 4152/4885 |
| US-20060241038-A1 | Therapeutic agent for Abeta related disorders | APP, BACE1, PSEN1 | PSEN1 3/4885PSEN2 6/4885APH1B 12/4885 |
| US-20060004013-A1 | Alzheimer's disease, senile dementia, Down syndrome or amyloidosis; 3E)-1-[(1S)-1-(4-fluorophenyl)ethyl]-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]piperidin-2-one; imidazolyl-functional compounds inhibit production of Amyloid beta 40 and Amyloid beta 42; low hygroscopicity; good solubility | PSEN1, APP, BACE1 | PSEN1 1/4885PSEN2 4/4885APH1B 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.